^
Association details:
| Biomarker: | PIK3CA G106_108del |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm). Add to Collection
Published date:
05/19/2021
Excerpt:
Cohort C: 36 pts with OTHERm only, any receptor subtype, treated with ALP in any combination....In Cohort C, rwPFS > 6 months was observed in 5 pts bearing: N345K, Q75E, R38C, G106_108del, and N345K/N1044K....there is evidence that OTHERm may differ in their degree of PI3K activation, oncogenicity, and ALP sensitivity.
